RxDoctor Payments Data

Brad Spagnolo, MD

Ophthalmology · Glen Burnie, MDNPI 1689679425

Payments from drug & device makers

$1,863in general payments, 2019–2025

Across 87 payments — averaging $21.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$267
  • Alcon$258
  • AbbVie$231
  • Oyster Point Pharma, Inc.$216
  • Tarsus Pharmaceuticals, Inc.$135
  • Bausch & Lomb Americas Inc.$106
  • plus $650 from 14 others

What the payments were for

  • Food & beverage$1,863100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,863 in reported general payments places this provider in the 55th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$402,293
Medicare patients
1,452
Services billed
3,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine26$34,774
MieboPerfluorohexyloctane/Pf13$21,749
XiidraLifitegrast12$14,431
LumiganBimatoprost16$13,155
RhopressaNetarsudil Mesylate16$9,963
Cyclosporine13$8,506
Travoprost12$4,876
Brimonidine Tartrate28$4,438
Latanoprost171$2,796
Bromfenac Sodium14$2,125
Loteprednol Etabonate13$1,976
Prednisolone Acetate28$1,404
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat35$786
Timolol Maleate23$628
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$231$47,92942 claims
Bausch & Lomb Americas Inc.Miebo, Xiidra$106$36,18025 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$98$1,97613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Glen Burnie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →